Pharmicell Co., Ltd. (005690.KS)

KRW 8000.0

(0.63%)

Market Cap (In KRW)

480.03 Billion

Revenue (In KRW)

56.22 Billion

Net Income (In KRW)

3.57 Billion

Avg. Volume

2.01 Million

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
4300.0-8870.0
PE
-
EPS
-
Beta Value
-1.237
ISIN
KR7005690003
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Hyun-Soo Kim
Employee Count
-
Website
https://www.pharmicell.com
Ipo Date
2000-01-04
Details
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.